Search results
Showing 6316 to 6330 of 8910 results
NICE recommends new treatment option for highly active multiple sclerosis
Thousands of people living with a form of multiple sclerosis (MS) will benefit from greater treatment choice, following new guidance from NICE.
NICE announces Professor Jonathan Benger as new Chief Executive
NICE Chairman, Sharmila Nebhrajani, today announced Professor Jonathan Benger CBE as incoming chief executive, with effect from Friday 19 December 2025 taking over from Dr Samantha Roberts.
Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]
Discontinued Reference number: GID-TA10065
Etirinotecan pegol for treating breast cancer with brain metastases [ID881]
Discontinued Reference number: GID-TA10066
Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]
Discontinued Reference number: GID-TA10070
Melanoma (advanced, unresectable, metastatic, NRAS mutation positive) - binimetinib [ID833]
Discontinued Reference number: GID-TA10074
Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]
Discontinued Reference number: GID-TA10081
Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin's lymphoma [ID1044]
Discontinued Reference number: GID-TA10087
Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]
Discontinued Reference number: GID-TA10088
Biotin for treating primary and secondary progressive multiple sclerosis [ID919]
Discontinued Reference number: GID-TA10099
Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]
Discontinued Reference number: GID-TA10105
Discontinued Reference number: GID-TA10109
Discontinued Reference number: GID-TA10110
Discontinued Reference number: GID-TA10126
Discontinued Reference number: GID-TA10133